GILEAD SCIENCES, INC.

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
Foster City, CA
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
Gilead Sciences, Inc. By: /s/ Andrew D. Dickinson
Source: Latest parsed Forms 3/4/5 signature
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for GILEAD SCIENCES, INC.

Form 4 holding 10%+ Owner

Arcellx, Inc.

Security class
Common Stock
Shares / value
6,720,803
Estimated value
$371,444,668
Report date
28 Dec 2023
Price
$55.27
Ownership
Direct
Form 4 holding 10%+ Owner

Arcus Biosciences, Inc.

Security class
Common Stock
Shares / value
31,424,760
Estimated value
$345,672,360
Report date
18 Feb 2025
Price
$11.00
Ownership
Direct
Form 4 holding 10%+ Owner

Xilio Therapeutics, Inc.

Security class
Prefunded Warrants (right to buy)
Shares / value
40,384,266
Estimated value
$21,601,543
Report date
13 Feb 2026
Price
$0.5349
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding 10%+ Owner

LEAP THERAPEUTICS, INC.

Security class
Common Stock
Shares / value
5,319,148
Estimated value
$15,159,572
Report date
10 Apr 2024
Price
$2.85
Ownership
Direct
Form 4 holding 10%+ Owner

HOOKIPA Pharma Inc.

Security class
Common Stock
Shares / value
18,759,465
Estimated value
$13,600,612
Report date
20 Dec 2023
Price
$0.7250
Ownership
Direct
Form 4 holding 10%+ Owner

Allovir, Inc.

Security class
Common Stock
Shares / value
16,635,286
Estimated value
$11,158,950
Report date
27 Jun 2023
Price
$0.6708
Ownership
Direct
Form 4 holding 10%+ Owner

Xilio Therapeutics, Inc.

Security class
Series A Warrants (right to buy)
Shares / value
13,335,000
Estimated value
Report date
05 Jun 2025
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding 10%+ Owner

Xilio Therapeutics, Inc.

Security class
Series C Warrants (right to buy)
Shares / value
13,335,000
Estimated value
Report date
05 Jun 2025
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding 10%+ Owner

ASSEMBLY BIOSCIENCES, INC.

Security class
Class A warrants to purchase Common Stock
Shares / value
1,147,960
Estimated value
Report date
08 Aug 2025
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding 10%+ Owner

ASSEMBLY BIOSCIENCES, INC.

Security class
Class B warrants to purchase Common Stock
Shares / value
1,147,960
Estimated value
Report date
08 Aug 2025
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding 10%+ Owner

Kyverna Therapeutics, Inc.

Security class
Series A-2 Convertible Preferred Stock
Shares / value
0
Estimated value
Report date
12 Feb 2024
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding 10%+ Owner

Kyverna Therapeutics, Inc.

Security class
Series B Convertible Preferred Stock
Shares / value
0
Estimated value
Report date
12 Feb 2024
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by GILEAD SCIENCES, INC.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .